Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

MESENCHYMAL STEM CELLS FOR MYOCARDIAL INFARCTION

Award Number: R01HL073709
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: HEALTH SERVICES
PERIOD OF PERFORMANCE START DATE: 07/15/2003
PERIOD OF PERFORMANCE END DATE: 06/30/2007

Group Awards By:

View Award Description

MESENCHYMAL STEM CELLS FOR MYOCARDIAL INFARCTION - DESCRIPTION (provided by applicant): Although cell transplant therapy has shown some promise in restoring tissue mass and improving left ventricular function after experimental myocardial infarction, the two major obstacles that must be overcome are 1) having an available and reliable source of cells, and 2) being able to administer the cells in a non-invasive fashion, especially in those patients who are at high risk for cardiac surgery. In this protocol we are proposing to use a commercial source of allogeneic rat mesenchymal stem cells (MSC). The ability to use allogeneic MSC to engraft infarcts early after coronary artery occlusion may constitute a significant therapeutic strategy, since the mesenchymal stem cells do not cause an immunologic response. The rat mesenchymal stem cells can be injected directly into the infarct or, in a non-invasive mode, administered intravenously. Preliminary studies have shown that when they are injected intravenously these cells "home" to areas of inflammation. The advantages of intravenous administration of cells as a clinical approach includes the ability to give one or repeated injections without the need for thoracotomy. However, the outcome of this approach on left ventricular function and healing (remodeling of the heart) is unknown. Therefore we propose to study mesenchymal stem cell implantation in a rat experimental myocardial infarct model. We will test both direct injection and intravenous injection in reperfused and non-reperfused infarcts. We will also determine whether there are differences in survival of the cells and their effects on LV function depending on the time of cell administration (early-within two hours of coronary artery occlusion, or late- four days after coronary artery occlusion). Immunohistochemistry of cells within the scar will include analysis for the Y chromosome (evidence of successful transplantation), cardiac troponin T, alpha actinin, tropomyosin, myosin heavy chain alpha and phospholamban, which will confirm that transplanted stem cells survived and either developed or did not develop a cardiac cell phenotype. The overall endpoints of this study will be to determine whether MSC therapy will enhance left ventricular function and reduce left ventricular dilation and remodeling after myocardial infarction, especially when commercially available cells are administered intravenously.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2006 ( Subtotal = $298,687 )
2006	2006	HOSPITAL OF THE GOOD SAMARITAN	616 SOUTH WITMER STREET	LOS ANGELES	CA	90017	LOS ANGELES	USA	Cardiovascular Diseases Research	000	4	5/18/2006	NON-COMPETING CONTINUATION	$298,687
														Subtotal = $298,687

Issue Date FY: 2005 ( Subtotal = $305,875 )
2005	2005	HOSPITAL OF THE GOOD SAMARITAN	616 SOUTH WITMER STREET	LOS ANGELES	CA	90017	LOS ANGELES	USA	Cardiovascular Diseases Research	000	3	6/9/2005	NON-COMPETING CONTINUATION	$305,875
														Subtotal = $305,875

Issue Date FY: 2004 ( Subtotal = $305,875 )
2004	2004	HOSPITAL OF THE GOOD SAMARITAN	616 SOUTH WITMER STREET	LOS ANGELES	CA	90017	LOS ANGELES	USA	Cardiovascular Diseases Research	000	2	5/18/2004	NON-COMPETING CONTINUATION	$305,875
														Subtotal = $305,875

Issue Date FY: 2003 ( Subtotal = $305,875 )
2003	2003	HOSPITAL OF THE GOOD SAMARITAN	616 SOUTH WITMER STREET	LOS ANGELES	CA	90017	LOS ANGELES	USA	Cardiovascular Diseases Research	000	1	7/5/2003	NEW	$305,875
														Subtotal = $305,875

Grand Total All Awards = $1,216,312

Top

All Categories

About

Search

Reports

Data Submission

Award Information

MESENCHYMAL STEM CELLS FOR MYOCARDIAL INFARCTION

Award Number: R01HL073709

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: HEALTH SERVICES

PERIOD OF PERFORMANCE START DATE: 07/15/2003

PERIOD OF PERFORMANCE END DATE: 06/30/2007

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer